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The global prevalence of diabetes is expected to rise from 171 million persons in 2000 to 366 million in 2030 \[[@CR1]\]. Prevalence estimates for dementia rise from 24 million in 2001 to 84 million in 2040 \[[@CR2]\]. There is compelling evidence for a link between diabetes and dementia, particularly in persons over 65 years of age. Longitudinal studies report a 1.5- to twofold increased risk of dementia, both Alzheimer's disease or vascular dementia, in individuals with diabetes compared with those without \[[@CR3]\].

Numerous cross-sectional studies have reported on neuropsychological functioning in non-demented patients with type 2 diabetes mellitus (e.g. \[[@CR4], [@CR5]\]). Systematic reviews of the literature report a cognitive profile of mild to moderate decrements in cognitive functioning in patients with type 2 diabetes \[[@CR6], [@CR7]\]. These decrements are most consistently found in information-processing speed, verbal memory and executive functioning \[[@CR6], [@CR7]\], possibly reflecting a diminished ability to efficiently process unstructured information \[[@CR8]\]. It is, however, less clear how these cognitive decrements evolve over time. Several longitudinal population-based studies have examined the risk of cognitive decline associated with type 2 diabetes in individuals who were not demented at baseline, but these studies have generally included only a limited number of psychometric tests or applied cognitive screening instruments, such as the Mini Mental State Examination, that may be criticised for lack of sensitivity \[[@CR9], [@CR10]\]. The present study provides detailed assessment of the evolution of cognitive decrements in patients with type 2 diabetes over a 4 year period, relative to control participants, using an elaborate neuropsychological examination. We hypothesised that type 2 diabetes is associated with accelerated cognitive decline.

Methods {#Sec2}
=======

***Participants*** The baseline examination (2002--2004) included 122 patients with type 2 diabetes and 56 control participants aged between 56 and 80 years, matched on age, sex and estimated IQ \[[@CR8], [@CR11]\]. Patients were recruited through general practitioners in the region. Control participants were recruited among the spouses or acquaintances of the patients. For inclusion the patients had to have had type 2 diabetes for at least 1 year, be functionally independent and Dutch speaking. Exclusion criteria for all participants were a psychiatric or neurological disorder (unrelated to diabetes) that could influence cognitive functioning and a history of alcohol or substance abuse or dementia. Control participants with a fasting blood glucose ≥7.0 mmol/l were also excluded. At follow-up 4 years later, seven participants had died, four could not be contacted and 59 were not willing or able to participate. Reasons for not participating were: lack of interest (*n* = 28); comorbidity (*n* = 22; three reported dementia \[two patients, one control\]); and other reasons (*n* = 9). The remaining 108 participants were re-examined between 2006 and 2008 (mean follow-up time 4.1 ± 0.4 years). One patient with type 2 diabetes was excluded because of severe comorbid disease and one control participant fulfilled the criteria for type 2 diabetes and was therefore excluded from the control group, leaving 106 participants (68 patients and 38 control participants) in the present analysis.The non-participants (*n* = 70) did not differ from the participants (*n* = 106) with regard to baseline age, sex or estimated premorbid IQ (all *p* \> 0.05). To control for possible selective loss at follow-up we examined the cognitive status of both non-participants and participants (±1 week after their participation in the follow-up examination) with the Dutch version of the Telephone Interview for Cognitive Status \[[@CR12]\], a 12 item screening instrument designed to identify persons with dementia \[[@CR13]\]. The Interview was slightly modified (TICS-m) by including a delayed word-list recall which resulted in a maximum score of 50 \[[@CR14]\]. The TICS-m was obtained from 43 of the 70 non-participants (i.e. 73% of the 59 non-participants who were still alive and could be contacted) and 99 of the 106 participants (93%). TICS-m scores were normally distributed across the whole study sample. The TICS-m performance for the non-participants was similar to the participants (non-participants mean score 35.4 ± 5.2, participants 36.5 ± 4.6, *F*\[1,140\] = 1.67, *p* = 0.20). Only three patients with type 2 diabetes (two non-participants, one participant) and two control participants (one non-participant, one participant) performed below the cut-off score of 28 (*χ*^2^\[1\] = 0.24, *p* = 0.62), which is indicative for cognitive impairment \[[@CR15]\]. Hence, among the non-participants four patients with type 2 diabetes (3% of baseline sample) and two controls (4% of baseline sample) had cognitive impairment based on self-reported dementia or a low TICS-m score (*χ*^2^\[1\] = 0.10, *p* = 0.76). The study was approved by the medical ethics committee of the University Medical Center Utrecht, Utrecht, the Netherlands. Written informed consent was obtained from all participants.

***Neuropsychological assessment*** At follow-up all participants performed an extensive neuropsychological assessment, identical to the baseline examination \[[@CR8]\]. Parallel versions were used for memory tests to control for possible material-specific learning effects \[[@CR16]\]. The neuropsychological assessment consisted of 11 verbal and non-verbal tasks, administered in a fixed order that took about 90 min to complete. The tasks were divided into five cognitive domains to reduce the amount of neuropsychological variables in the analysis and for clinical clarity \[[@CR8]\]. This division was made a priori, according to standard neuropsychological practice and cognitive theory, as described in detail in Lezak et al. \[[@CR16]\]. The domain 'abstract reasoning' was assessed by Raven Advanced Progressive Matrices (12 item short form). The domain 'memory' included four subdomains: 'working memory' assessed by the forward and backward digit span of the Wechsler Adult Intelligence Scale, 3rd edition (WAIS-III) and the Corsi Block-tapping Task (the product scores of the span length × the number of correctly recalled sequences were recorded \[[@CR17]\]); 'immediate memory and learning rate', including verbal memory assessed by the Rey Auditory Verbal Learning Test and visual memory assessed by the Location Learning Test; 'forgetting rate' assessed by the delayed task of the Rey Auditory Verbal Learning Test and the Location Learning Test; and 'incidental memory' assessed by the delayed trial of the modified Taylor Complex Figure. The domain 'information-processing speed' was assessed by the Trail-making Test---Part A, the Stroop Color--Word Test (Parts I and II), and the subtest Digit Symbol of the WAIS-III. The domain 'attention and executive function' was assessed by the Trail-making Test---Part B (ratio score), the Stroop Color--Word Test (Part III; ratio score), the Brixton Spatial Anticipation Test, a letter fluency test using the 'N' and 'A', and category fluency (animal naming). The domain 'visuoconstruction' was assessed by the copy trial of the modified Taylor Complex Figure.To compare the five different cognitive domains between the two groups the raw test scores were standardised into *z* scores per cognitive domain. These *z* scores were calculated by using the pooled mean of baseline scores of the whole study sample. The *z* score for each domain was derived by calculating the mean of the *z* scores for tests comprising that domain. Depressive symptoms were assessed with the Dutch version of the Beck Depression Inventory, 2nd edition (BDI-II \[[@CR18]\]). The total score on this self-rated depressive symptoms inventory and the proportion of persons scoring \>13 were recorded \[[@CR19]\].

***Medical history and biometric measurements*** Procedures at baseline and follow-up were identical \[[@CR8]\]. Medical history was assessed with a standardised questionnaire addressing diabetes duration, medication use, history of cardiovascular disease (including stroke), smoking and alcohol consumption. Fasting glucose, HbA~1c~ and cholesterol levels were measured with standard laboratory testing. Blood pressure was measured in a seated position at three time-points during the half-day visit (Omron MX3; Omron, Mannheim, Germany). Hypertension was defined as a systolic blood pressure \>160 mmHg, a diastolic blood pressure \>95 mmHg or self-reported use of blood-pressure-lowering medication. 'Any macrovascular event' was defined as a history of myocardial infarction, stroke, or surgery or endovascular treatment for coronary, carotid or peripheral (legs, abdominal aorta) artery disease. Retinopathy was defined as a score of ≥1.5 on the Wisconsin Epidemiologic Study of Diabetic Retinopathy scale \[[@CR20]\]. Neuropathy was defined as a score ≥6 on a modified version of the Toronto Clinical Neuropathy Scoring System \[[@CR21], [@CR22]\].

***Statistical analysis*** Between-group differences in characteristics were analysed with analysis of variance for continuous variables, Mann--Whitney *U* tests for non-parametric data and *χ*^2^ tests for proportions. The primary outcome measures were the *z* scores of the five cognitive domains, which were analysed with repeated-measures ANOVA, including the effect of time, group and the time × group interaction. The effect of time reflects the mean change in cognitive performance over time for the whole study sample; the effect of group reflects the mean difference between the patients with type 2 diabetes and the control group; the time × group interaction reflects the additional change over time attributable to diabetes status. *p* values \<0.05 were considered statistically significant.In a secondary analysis additional adjustment for BDI-II depressive symptoms was performed to examine a possible confounding effect of depression. Moreover, within the diabetes group cognitive functioning (domains information processing speed and attention and executive functioning) was compared between patients with high or low baseline HbA~1c~ (dichotomised at the median level of 6.6 mmol/l), with or without baseline hypertension and with or without 'any macrovascular event' at baseline.

Results {#Sec3}
=======

Table [1](#Tab1){ref-type="table"} shows the characteristics of the patients with type 2 diabetes and the control group at baseline. The groups were similar in age, estimated IQ and sex distribution. As expected, between-group differences in glycaemic control, vascular risk factors and vascular events were still present at the follow-up examination after 4 years. At baseline six (9%) patients were treated with diet only, 42 (62%) used oral glucose-lowering medication and 20 (29%) used insulin. The baseline prevalence of retinopathy and neuropathy was 32% and 35%, respectively. Table 1Baseline characteristics of the patients with type 2 diabetes and the control groupCharacteristicBaselineFollow-upType 2 diabetesControl group*p* valueType 2 diabetesControl group*p* value*n*6838--6838--Age (years)65.6 ± 5.664.8 ± 4.80.4469.8 ± 5.668.9 ± 4.80.44Male sex (*n*)32 (47%)19 (50%)0.77------Educational level (median (IQR))4 (3--5)4 (4--5)0.87------Estimated IQ (points)100 ± 16103 ± 130.3997 ± 1598 ± 150.64Diabetes duration (years)9.1 ± 6.3----------HbA~1c~ (%)6.9 ± 1.15.5 ± 0.3\<0.0017.2 ± 1.05.7 ± 0.4\<0.001Hypertension^a^49 (72%)11 (29%)\<0.00153 (78%)19 (50%)\<0.01BMI (kg/m^2^)27.9 ± 4.026.7 ± 5.20.1928.4 ± 4.826.7 ± 4.50.09Total cholesterol (mmol/l)5.0 ± 0.95.9 ± 1.2\<0.0014.5 ± 1.05.9 ± 1.0\<0.001History of stroke3 (4%)1 (3%)0.653 (4%)1 (3%)0.65Any macrovascular event^b^18 (27%)2 (5%)0.00720 (29%)3 (8%)0.01Beck Depression Inventory7.2 ± 5.04.4 ± 3.50.0058.5 ± 7.05.5 ± 5.10.03Beck Depression Inventory \>135 (9%)0 (0%)0.079 (16%)1 (3%)0.04Data are presented as mean ± SD or *n* (%) unless otherwise specified^a^Defined as systolic blood pressure \>160 mmHg, diastolic blood pressure \>95 mmHg or use of blood-pressure-lowering medication^b^Defined as a history of myocardial infarction, stroke, or surgery or endovascular treatment for coronary, carotid of peripheral (legs, abdominal aorta) artery disease*p* values derived using univariate analysis of varianceIQR, interquartile range

Table [2](#Tab2){ref-type="table"} shows the raw test scores of the neuropsychological examination for both groups at baseline and follow-up. To limit the number of comparisons, only the differences in domain scores were compared statistically (Table [3](#Tab3){ref-type="table"}). As is shown in Fig. [1](#Fig1){ref-type="fig"} the results of the repeated-measures ANOVA demonstrated a significant decline in performance over 4 years for the whole sample on the domains abstract reasoning and attention and executive functions (mean change in *z* scores −0.16, *F*\[1,93\] = 4.83, *p* = 0.03 and −0.29, *F*\[1,103\] = 25.59, *p* \< 0.001, respectively). A significant main effect of group was found in information-processing speed (mean difference in *z* scores for patients with type 2 diabetes compared with controls: −0.37, *F*\[1,102\] = 6.68, *p* \< 0.05) and attention and executive functions (−0.25, *F*\[1,103\] = 3.01, *p* \< 0.05), and a trend in the same direction on memory (−0.16, *F*\[1,103\] = 3.42, *p* = 0.07). There were no significant time × group interactions, although there was a trend towards interaction for visuoconstruction (*p* = 0.07). Additional adjustment for BDI-II score or exclusion of persons with a BDI-II score \>13 did not change the results. Visual inspection of the distribution of the individual *z* scores for each domain did not reveal differences between the diabetes group and the control group. This indicated that it was the diabetes group as a whole that had a worse mean performance, rather than a subgroup of patients with type 2 diabetes performing in the lowest part of the *z* score distribution. Table 2Raw test scores of the patients with type 2 diabetes and the control group at the baseline and follow-up examinationTestType 2 diabetes (*n* = 68)Control group (*n* = 38)BaselineFollow-upBaselineFollow-upRaven APM (short form)6.3 ± 2.96.3 ± 2.97.3 ± 2.16.5 ± 2.4WAIS-III Digit Span Forward (product score)45.1 ± 20.541.0 ± 20.047.6 ± 19.148.6 ± 20.6 Backward (product score)23.1 ± 15.721.0 ± 15.032.5 ± 23.027.5 ± 22.0Corsi Block-tapping Test Forward (product score)38.0 ± 13.836.5 ± 11.737.8 ± 9.537.2 ± 11.3 Backward (product score)37.1 ± 13.837.4 ± 13.641.3 ± 12.838.8 ± 13.2Rey Auditory Verbal Learning Test Total trials 1−539.2 ± 9.038.4 ± 10.843.1 ± 11.443.4 ± 10.8 Delayed recall7.6 ± 2.77.7 ± 2.88.7 ± 2.89.2 ± 3.1 Recognition28.2 ± 1.928.5 ± 1.729.1 ± 1.429.0 ± 1.5Location Learning Test Total trials 1−5^a^24.9 ± 21.023.7 ± 22.124.8 ± 19.920.5 ± 17.1 Learning index0.59 ± 0.280.54 ± 0.310.66 ± 0.280.61 ± 0.29 Delayed trial^a^2.0 ± 3.32.5 ± 3.51.7 ± 2.91.7 ± 2.8Complex Figure Test Copy32.4 ± 3.933.7 ± 2.733.0 ± 3.333.1 ± 3.0 Delay17.4 ± 6.617.8 ± 6.119.9 ± 4.518.4 ± 5.2Stroop Color--Word Test Part I^a^50.4 ± 12.851.2 ± 9.647.0 ± 8.946.1 ± 7.6 Part II^a^65.1 ± 13.666.6 ± 11.661.3 ± 14.262.8 ± 13.8 Part III^a^124.6 ± 46.6135.2 ± 46.3113.1 ± 45.5118.6 ± 41.5TMT Part A^a^49.5 ± 21.047.1 ± 22.938.6 ± 9.738.1 ± 12.1 Part B^a^114.2 ± 44.2138.0 ± 83.889.1 ± 25.197.1 ± 30.7WAIS-III Digit Symbol54.9 ± 16.850.4 ± 15.756.6 ± 12.256.6 ± 13.5Verbal fluency Letter (mean of N+A)10.4 ± 4.89.7 ± 4.212.0 ± 4.111.1 ± 4.0 Category (Animals)33.8 ± 10.031.4 ± 10.134.1 ± 7.731.4 ± 10.1Brixton Spatial Anticipation Test^a^20.8 ± 7.322.1 ± 6.318.1 ± 6.622.1 ± 6.3Data are mean ± SD^a^Higher test scores reflect worse performanceRaven APM, Raven Advanced Progressive Matrices; RALVT, Rey Auditory Verbal Learning Test; LLT, Location Learning Test; TMT, Trail-making TestTable 3Differences in cognitive domain scores for patients with type 2 diabetes and the control group at the baseline and follow-up examinationDomainsMean change over time^a^Mean difference between T2DM and control group^b^Time × group interaction *p* valueAbstract reasoning−0.16 (−0.30 to −0.02)−0.17 (−0.57 to 0.22)0.20Memory−0.06 (−0.14 to 0.02)−0.16 (−0.34 to 0.01)0.15Information-processing speed−0.05 (−0.14 to 0.04)−0.37 (−0.69 to −0.05)0.23Attention and executive functions−0.29 (−0.40 to −0.17)−0.25 (−0.49 to −0.01)0.37Visuoconstruction0.16 (−0.06 to 0.38)−0.06 (−0.36 to 0.24)0.07Data are *z* scores (95% CI) analysed with repeated-measures analysis of variance^a^For the whole sample^b^Control group is referenceT2DM, type 2 diabetes mellitusFig. 1Cognitive functioning (mean standardised domain score ± SEM) for the patients with type 2 diabetes (white circles; *n* = 68) and the control group (black circles; *n* = 38) at baseline (BL) and 4 year follow-up (FU): **a** abstract reasoning, main effect of time *p* = 0.03, main effect of group *p* = 0.39, time × group interaction *p* = 0.20; **b** memory, main effect of time *p* = 0.16, main effect of group *p* = 0.07, time × group interaction *p* = 0.15; **c** information-processing speed, main effect of time *p* = 0.28, main effect of group *p* = 0.02, time × group interaction *p* = 0.23; **d** attention and executive functioning, main effect of time *p* \< 0.001, main effect of group *p* = 0.04, time × group interaction *p* = 0.37; **e** visuoconstruction, main effect of time *p* = 0.15, main effect of group *p* = 0.71, time × group interaction *p* = 0.07. *p* values indicate the results of the repeated-measures ANOVA

In secondary analyses within the diabetes group no significant group differences or time × group interactions with regard to HbA~1c~ level were found (information-processing speed mean group difference \[95% CI\] = 0.07 \[−0.37, 0.51\]; attention and executive functions −0.08 \[−0.38, 0.23\]) or the presence of hypertension (information-processing speed 0.11 \[−0.38, 0.60\]; attention and executive functions 0.01 \[−0.33, 0.34\]). For patients with type 2 diabetes with 'any macrovascular event' there was a trend toward a worse performance on information-processing speed (−0.46 \[−0.95, 0.03\]), but no differences were found on attention and executive functions (−0.19 \[−0.53, 0.15\]).

Discussion {#Sec4}
==========

Patients with type 2 diabetes showed moderate decrements in cognitive functioning compared with control participants matched for age, sex and estimated IQ, both at baseline and after 4 year follow-up in the information-processing speed and attention and executive functioning domains. After 4 years a decline in abstract reasoning and attention and executive functioning was found for the whole sample, but no evidence was shown for accelerated decline in the patients with type 2 diabetes.

The profile of cognitive decrements and the size of the effects observed in the present study are comparable with the results from previous cross-sectional studies on cognition in type 2 diabetes, which show small to moderate decrements (effect sizes −0.3 to −0.6) particularly in the domains information-processing speed, executive functioning and memory \[[@CR6]\]. Interestingly, the effect sizes of cross-sectional studies in patients with different stages of type 2 diabetes or even prediabetic stages are remarkably similar, generally ranging from −0.3 to −0.6 \[[@CR4], [@CR23]--[@CR25]\], indicating that these decrements may develop in the early stage of the disease and progress only gradually thereafter. Our findings on the domain visuoconstruction were dissimilar to the other domains, as the performance of the patients with type 2 diabetes tended to improve. We have no certain explanation for this observation, but the fact that this domain only comprised a single test, in contrast to the other domains, may have affected the reliability of this domain score and increased the potential impact of confounding factors such as motivation, ceiling effects or practice effects, particularly for those participants with an initial worse performance.

To date, longitudinal studies that examine the cognitive profile of patients with type 2 diabetes and control participants by means of a detailed neuropsychological test battery are scarce. Two previous case--control studies, with smaller samples of patients with type 2 diabetes than the present study, did not consistently observe accelerated cognitive decline in patients with type 2 diabetes after a 3 to 4 year follow-up \[[@CR26], [@CR27]\]. Longitudinal population-based studies, which included less detailed assessment of cognitive functioning than the present study, showed moderate differences in cognitive performance between patients with type 2 diabetes and controls at baseline and follow-up \[[@CR9], [@CR10], [@CR28], [@CR29]\], similar to the differences found in the present study. Some of these studies also observe a modest accelerated decline after a 3 to 6 year period on a subset of the cognitive measures \[[@CR9], [@CR10], [@CR29]\] of approximately 1.5 times the decline of the non-diabetic participants. Apparently, no marked accelerated cognitive decline is found in the majority of patients with type 2 diabetes relative to persons without type 2 diabetes. This is in contrast with prototypic diabetic complications, such as retinopathy, nephropathy and neuropathy, for which prevalence and severity clearly increase with duration of diabetes and exposure to elevated glucose levels. Future aetiological studies should answer the question why cognitive decrements can already be found in prediabetic stages, or at the time of diabetes diagnosis, and progress only slowly thereafter. In prediabetic stages exposure to vascular risk factors such as hypertension, dyslipidaemia and obesity may play a role. Although acute effects of elevated blood glucose levels on cognitive functioning have been reported \[[@CR30]\], the present findings suggest that long-term exposure to elevated blood glucose levels apparently do not have a major impact on cognition in patients with type 2 diabetes, a finding in line with recent observations in adult patients with type 1 diabetes \[[@CR31]\].

The question also is how these findings relate to the 1.5- to twofold increased risk of dementia that is observed in individuals with type 2 diabetes \[[@CR3]\]. A likely explanation is that the subtle cognitive decrements that are found in non-demented populations do not necessarily evolve into frank cognitive decline in all individuals, but rather that within the population of older patients with type 2 diabetes, severe cognitive decline only occurs in a subgroup of persons, possibly in interaction with other risk factors such as the apolipoprotein E status \[[@CR32]\], hypertension \[[@CR33]\] or the metabolic syndrome \[[@CR34]\]. Furthermore, particularly below the age of 70 years, incident dementia is relatively rare (annual incidence \<1% per year \[[@CR35]\]). This makes dementia a fundamentally different cognitive outcome measure than the more subtle cognitive decrements that are addressed in the present study, which show a normal distribution across the whole study sample.

The present detailed analysis of the neuropsychological profile associated with type 2 diabetes revealed a pattern of modest decrements in information-processing speed and attention and executive functioning, with a non-significant trend in the same direction for memory. This profile appears to reflect an overall diminished performance level rather than deficits in specific cognitive functions \[[@CR36]\] and resembles the pattern that is found in normal ageing \[[@CR36]\].

The principal strength of the present study is the detailed neuropsychological examination that was performed twice over a 4 year interval in a relatively large sample of patients with type 2 diabetes. Limitations include possible selection bias due to selective attrition during the follow-up period. The results of the TICS-m showed that selection bias due to drop out of persons with severely impaired cognitive functioning was limited. Nevertheless, during follow-up of the non-participants we observed that several persons with marked cognitive decline dropped out of the study, albeit at a low rate that was similar in the two groups. Moreover, the reduction in sample size at the follow-up examination may have limited the power of the statistical analyses, particularly with regard to the time × group interactions.

In summary, the results of the present study indicate that in functionally independent patients with type 2 diabetes cognitive decrements are modest in size and decline is largely within the range of what can be viewed in normal ageing. Apparently, diabetes-related cognitive changes progress slowly over a prolonged period of time, probably much longer than the 4 years of follow up in the present study.

This study was supported by grant 2003.01.004 of the Dutch Diabetes Research Foundation. The research of G. J. Biessels and R. P. C. Kessels is supported by a high potential grant from Utrecht University. The Utrecht Diabetic Encephalopathy Study Group consists of (baseline and follow-up study, in alphabetical order): Department of Clinical Neurophysiology: A. C. van Huffelen; Department of Internal Medicine: H. W. de Valk; Julius Center for Health Sciences and Primary Care: A. Algra, G. E. H. M. Rutten; Department of Medical Pharmacology: W. H. Gispen; Department of Neurology: A. Algra, G. J. Biessels, L. J. Kappelle, S. M. Manschot, J. van Gijn; Department of Neuropsychology: Y. Reijmer, E. van den Berg; Department of Experimental Psychology and Helmholtz Instituut: A. M. A. Brands (currently Zuwe Hofpoort; Regionaal Psychiatrisch Centrum, Woerden, the Netherlands), E. H. F. de Haan (currently University of Amsterdam, Amsterdam, the Netherlands), R. P. C. Kessels (currently Donders Institute for Brain, Cognition and Behaviour; Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands); Department of Radiology and Image Sciences Institute: J. de Bresser, C. Jongen, W. Mali, A. Tiehuis, J. van der Grond (currently Leiden University Medical Center, Leiden, the Netherlands), M. Viergever, all part of the University Medical Center, Utrecht, the Netherlands. Patients were recruited through the community-based 'Utrecht Diabetes Programma (UDP)' and the 'IJsselstein Diabetes Project' (mentor: Ph. L. Salomé). The UDP is a long-running collaborative project between general practitioners and a hospital-based endocrinologist, with the aim to improve the level of care for patients with type 2 diabetes in the community without referral to the hospital.

**Duality of interest** The authors declare that there is no duality of interest associated with this manuscript.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

BDI-II

:   Beck Depression Inventory, 2nd edition

TICS-m

:   Modified Telephone Interview for Cognitive Status

WAIS-III

:   Wechsler Adult Intelligence Scale, 3rd edition
